AlloVir CEO Departs, CFO Steps In

Dow Jones

2024-12-21

By Katherine Hamilton

AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place.

Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said.

AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris Therapeutics.

To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals.

Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 20, 2024 17:40 ET (22:40 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2493408341"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493408341\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2493408341?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-21 06:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493408341","market":"fut","top_or_hot":-1,"title":"AlloVir CEO Departs, CFO Steps In","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place. \n</p>\n<p>\n  Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said. \n</p>\n<p>\n  AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals. \n</p>\n<p>\n  Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 17:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AlloVir CEO Departs, CFO Steps In</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlloVir CEO Departs, CFO Steps In\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2024-12-21 06:40</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place. \n</p>\n<p>\n  Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said. \n</p>\n<p>\n  AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>. \n</p>\n<p>\n  To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals. \n</p>\n<p>\n  Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year. \n</p>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 17:40 ET (22:40 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALVR","symbol_name":"AlloVir, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2493408341","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493408341","pubTimestamp":1734734400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place.Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said.AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris Therapeutics.To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals.Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALVR":"AlloVir, Inc."},"translate_title":"AlloVir首席执行官离职，首席财务官接任","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALVR":1},"content_text":"By Katherine Hamilton \n\n\n  AlloVir said its chief executive Diana Brainard is departing and the company has appointed its CFO to take her place. \n\n\n  Brainard's departure became effective Thursday and she resigned as director of the cell therapy company, the company said on Friday. Her resignation did not result from any disagreement with the company related to its operations, policies or practices, AlloVir said. \n\n\n  AlloVir said it plans to give Brainard a lump sum in cash worth 36 months of her base salary, which was $623,432 in 2023, according to a filing. She is also set to receive $100,000 for completing the proposed merger with Kalaris Therapeutics. \n\n\n  To succeed Brainard, AlloVir appointed Vikas Sinha, who has been serving as chief financial officer since 2019. Sinha, 61, co-founded ElevateBio and was previously CFO of Alexion Pharmaceuticals. \n\n\n  Sinha' earned a total compensation of $2.9 million as CFO in 2023. Brainard made a total of $6.1 million as CEO that year. \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 17:40 ET (22:40 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1}}}